Navigation Links
Viprinex in Medical News

Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

...and to proceed expeditiously in the process," stated William Fletcher, acting Chief Executive Officer. Assuming accrued costs associated with the viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash,...

Neurobiological Technologies Reports Second Quarter Financial Results

...ently in two Phase III clinical trials. We believe viprinex has the potential to double the treatment window o...aZeneca's neuroprotectant drug candidate." About viprinex Phase 3 Trial Program viprinex is an investigational agent with multiple novel me...

Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ

...ng drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The company is currently developing viprinex (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. http://www.ntii.com A registrati...

Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke

...inex(TM) (ancrod), for the treatment of acute ischaemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper. "The ancrod data presented this week in Glasgow draws positive c...
Viprinex in Medical Technology

Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data

- Company Plans to Announce Interim Results in January 2009 and Final Trial Data in mid-2009 - EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that following a meeting with the U.S. Food ...

Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)

Investigational Drug Being Pursued for the Treatment of Ischemic Stroke GLASGOW, Scotland, May 31, 2007 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical devel...

Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis

...an acute ischemic stroke, comparing treatment with viprinex to treatment with placebo. The DSMB determined tha...he study. "We are deeply disappointed that viprinex did not improve overall patient outcomes in our cl...adcount if we determine that future development of viprinex is not warranted." About Neurobiological T...

Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials

...coauthor of the retrospective analysis. "Earlier viprinex trials used a dosing regimen that infused the drug...urrently conducting two Phase 3 clinical trials of viprinex to investigate whether ancrod can safely and effec...have enrolled over 500 patients. NTI believes that viprinex can be administered up to six hours after the onse...

Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials

... interim analysis across the two studies. NTI is currently studying whether viprinex is safe and effective for treating acute ischemic stroke when given within ...as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double th...

Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference

...rth American and European Phase 3 stroke trials of viprinex involving more than 1,700 patients. viprinex has been shown to rapidly reduce blood levels of f...enefit from this approach. "The prior studies of viprinex showed improved efficacy, but used a dosing regime...

Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)

...nctional outcome at 3 months. This is the fifth DSMB meeting for the Ancrod Stroke Program (ASP). The two trials are: -- ASP-I, the Study of Acute viprinex for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod in Subjects Beginning Treatment Within 6 Hours of the Ons...
Viprinex in Biological Technology

Neurobiological Technologies Announces Suspension of Viprinex Development

EMERYVILLE, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) today announced that, following a detailed analysis of the recent interim results of the Viprinex(TM) clinical trial, the company has decided not to develop Viprinex further for ...

Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program

EMERYVILLE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it will hold a conference call on Monday, October 13, to provide an update on the Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke. Hosting t...

Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009

...l drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifica... sale of XERECEPT(R) by Celtic, the development of viprinex for acute ischemic stroke by NTI, delays or other ...blems with our clinical trials, the outcome of the viprinex interim analysis, the time and costs for obtaining...

Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results

...eiman, president and chief executive officer. "The viprinex studies have recently surpassed a total of 600 pat... will constitute a major go/no-go decision for the viprinex program, since it is the first efficacy assessment...ring Board (DSMB). For the trial to pass futility, viprinex must demonstrate predetermined efficacy criteria. ...

Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI...

Neurobiological Technologies Sets Date for First Quarter Financial Results

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI...

Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine

... advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acu...
Other Tags
(Date:8/4/2015)... ... August 05, 2015 , ... Renowned review site BestMillionaireDatingSites.com recently refreshed its list ... has been ranked as the best dating service in the segment. , A representative ... It is essential that people find the right dating platform so that they can ...
(Date:8/4/2015)... ... August 05, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting more than 700,000 members and over 200 ...
(Date:8/4/2015)... ... ... NOVA Pride , Northern Virginia’s largest and newest LGBTQ nonprofit organization, ... join them in paving “The Road Ahead” at the second annual Northern Virginia Pride ... 2015, from 12-9pm. In order to ensure the success of this important event, NOVA ...
(Date:8/4/2015)... ... 2015 , ... How cool is it to check in at your favorite ... "Now" feature will soon allow you to do just that. , Ahhaa is releasing ... the now feature. , Users will soon get to share what inspires them about ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Statement by Paul ... the introduction of the Mental Health Reform Act of 2015 by Senators ... mental health reform a reality in America. , “This legislation and H.R. ...
Breaking Medicine News(10 mins):Health News:BestMillionaireDatingSites.com Publishes Reviews of the Best Dating Sites for Wealthy Singles 2Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 2Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 3Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 4Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
Other Contents